Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · IEX Real-Time Price · USD
13.03
-0.25 (-1.88%)
May 2, 2024, 3:30 PM EDT - Market open
Sage Therapeutics Employees
Sage Therapeutics had 487 employees on December 31, 2023. The number of employees decreased by 202 or -29.32% compared to the previous year.
Employees
487
Change (1Y)
-202
Growth (1Y)
-29.32%
Revenue / Employee
$186,990
Profits / Employee
-$1,033,150
Market Cap
784.17M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 487 | -202 | -29.32% |
Dec 31, 2022 | 689 | 218 | 46.28% |
Dec 31, 2021 | 471 | 173 | 58.05% |
Dec 31, 2020 | 298 | -377 | -55.85% |
Dec 31, 2019 | 675 | 38 | 5.97% |
Dec 31, 2018 | 637 | 380 | 147.86% |
Dec 31, 2017 | 257 | 122 | 90.37% |
Dec 31, 2016 | 135 | 73 | 117.74% |
Dec 31, 2015 | 62 | 31 | 100.00% |
Dec 31, 2014 | 31 | 8 | 34.78% |
Dec 31, 2013 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
SAGE News
- 5 hours ago - An Investigation Has Commenced on Behalf of Sage Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SAGE Losses. - Accesswire
- 4 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE - PRNewsWire
- 6 days ago - INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 7 days ago - Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress - Business Wire
- 15 days ago - Sage Therapeutics' stock plunges as Parkinson's drug trial disappoints - Market Watch
- 15 days ago - Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study - Reuters
- 15 days ago - Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease - Business Wire
- 21 days ago - Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 - Business Wire